Biotech · Private company · New York City, NY, US
Sparian Biosciences, Inc
Track this companyFree. Adds Sparian Biosciences, Inc to your Dealase workspace and tells you when its record changes.
Clinical trials21 recruiting or active
Pipeline programs2From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline2
- SBS-1000Phase 1 · PainClinicalTrials.gov · fetched Nov 12, 2026
- SBS-147Phase 1 · Pain AcuteClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials2
- Phase 1 Study of SBS-147 in Healthy AdultsPHASE1 · RECRUITING · started Jan 8, 2026ClinicalTrials.gov NCT07335913 · fetched Nov 12, 2026
- A Phase 1, Randomized, Placebo-Controlled Safety and Tolerability Study Of Intravenous SBS-1000 in Healthy AdultsPHASE1 · COMPLETED · started Jan 30, 2023ClinicalTrials.gov NCT05721287 · fetched Nov 12, 2026
NIH awards5
- Clinical Development of SBS-147: First-in-class Oral Arylepoxamide Agonist for PainFiscal year 2026 · $3.1MNIH RePORTER 5UG3DA064392-02 · fetched Nov 12, 2026
- Clinical Development of SBS-147: First-in-class Oral Arylepoxamide Agonist for PainFiscal year 2025 · $3.1MNIH RePORTER 1UG3DA064392-01 · fetched Nov 12, 2026
- Development of SBS-226, a MOR agonist / DOR antagonist, for OUDFiscal year 2025 · $4MNIH RePORTER 5UG3DA059278-02 · fetched Nov 12, 2026
- Development of SBS-226, a MOR agonist / DOR antagonist, for OUDFiscal year 2024 · $4MNIH RePORTER 1UG3DA059278-01A1 · fetched Nov 12, 2026
- Development of sigma receptor/DAT dual-targeting compounds to treat stimulant use disorderFiscal year 2024 · $4MNIH RePORTER 5UG3DA058553-02 · fetched Nov 12, 2026